GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Other Gross PPE

Xeris Biopharma Holdings (LTS:0A8E) Other Gross PPE : $10.3 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Other Gross PPE?

Xeris Biopharma Holdings's Other Gross PPE for the quarter that ended in Mar. 2024 was $10.3 Mil.

Xeris Biopharma Holdings's quarterly Other Gross PPE stayed the same from Sep. 2023 ($10.1 Mil) to Dec. 2023 ($10.1 Mil) but then increased from Dec. 2023 ($10.1 Mil) to Mar. 2024 ($10.3 Mil).

Xeris Biopharma Holdings's annual Other Gross PPE increased from Dec. 2021 ($8.8 Mil) to Dec. 2022 ($8.9 Mil) and increased from Dec. 2022 ($8.9 Mil) to Dec. 2023 ($10.1 Mil).


Xeris Biopharma Holdings Other Gross PPE Historical Data

The historical data trend for Xeris Biopharma Holdings's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Other Gross PPE Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial 7.07 7.31 8.77 8.91 10.14

Xeris Biopharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.51 10.01 10.14 10.14 10.26

Xeris Biopharma Holdings Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Xeris Biopharma Holdings (LTS:0A8E) Business Description

Traded in Other Exchanges
Address
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings (LTS:0A8E) Headlines

No Headlines